Iksuda Therapeutics (Iksuda), an emerging biotechnology company focused on developing antibody- based therapies for the treatment of cancer, has signed a licensing agreement with Femtogenix Ltd., a next-generation ADC payload company, under which, Iksuda will use FGX’s sequence-selective DNA-interactive payload molecules to advance its lead ADC to the clinic, with the goal of targeting difficult-to-treat solid tumors.   Leveraging FGX’s highly potent and broad-acting DNA mono-alkylating payloa...